All issues
Volume 67 (1991)
- Issue 12 Pages 1295-
- Issue 11 Pages 1231-
- Issue 10 Pages 1147-
- Issue 9 Pages 14-
- Issue 8 Pages 811-
- Issue 7 Pages 755-
- Issue 6 Pages 655-
- Issue 5 Pages 587-
- Issue 4 Pages 19-
- Issue 3 Pages 175-
- Issue 2 Pages 57-
- Issue 1 Pages 1-
- Issue Supplement-3 Pa･･･
- Issue Supplement-2 Pa･･･
- Issue Supplement-1 Pa･･･
Predecessor
Volume 68, Issue 2
Displaying 1-6 of 6 articles from this issue
- |<
- <
- 1
- >
- >|
-
Eiji Ishikawa1992 Volume 68 Issue 2 Pages 63-70
Published: February 20, 1992
Released on J-STAGE: September 24, 2012
JOURNAL FREE ACCESSTwo methods for ultrasensitive immunoassay of peptide hormones are presented. One is to reduce the nonspecific binding of labeled reactants in two-site immunoassay by transfer of immune complexes containing labeled reactants from one solid phase to another. The other is a novel noncompetitive immunoassay method for small peptides, in which peptides are biotinylated and subsequently measured by two-site assay using anti-peptide antibody and avidin (streptavidin).View full abstractDownload PDF (622K) -
Masao IGARASHI1992 Volume 68 Issue 2 Pages 71-80
Published: February 20, 1992
Released on J-STAGE: September 24, 2012
JOURNAL FREE ACCESSRecent researches on inhibin and activin were reviewed. This mini review contains brief history of researches on inhibins and activins, criteria, chemistry, the site of production of these two hormones, assay method (bio- and radioimmunoassay), changes of serum inhibin levels in normal physiologic states and in various pathologic states of men and women, actions of inhibins and activins upon FSH and LH secretion from the pituitary, upon other pituitary functions, upon brain functions, erythropoiesis, erythroleukemia, bone and bone marrow, immunology, other organs such as liver, pancreas, adrenals, placenta, Xenopus oocyte and general cell proliferation, paracrine and autocrine actions of these hormones inside the ovary and the testis, activin receptor, inhibin receptor, follistatin, effects of exogenous administration of recombinant inhibin and activin, and TGF-β super gene family.View full abstractDownload PDF (1023K) -
Chihiro IHARA, Akira SHIMATSU, Tsutomu TANOH, Masaki HARADA, Tomoyuki ...1992 Volume 68 Issue 2 Pages 81-88
Published: February 20, 1992
Released on J-STAGE: September 24, 2012
JOURNAL FREE ACCESSA 33-year-old man with hypopituitarism is documented. He was born at breech presentation without asphyxia. He was the shortest in his class throughout his school days. He kept slowly growing and reached 172.8cm at the age of 33. He was devoid of secondary sexual characteristics. Endocrinological studies showed panhypopituitarism with elevated levels of plasma TSH (15.0μU/ml). TRH administration resulted in a marked increase in plasma TSH. Posterior pituitary function was normal. MR imaging showed transection of the pituitary stalk and the presence of ectopic and eutopic posterior lobes. The replacement of corticosteroid was initiated, and exaggerated response of TSH to TRH disappeared. Delayed bone maturation due to hypogonadism and hypothyroidism was one of the reasons why he had normal height without GH therapy. The significance of his peculiar MRI findings remains to be determined.View full abstractDownload PDF (1087K) -
Akira SHIMATSU, Hiroo IMURA, Minoru IRIE, Shoichi NAKAGAWA, Yoshio GOT ...1992 Volume 68 Issue 2 Pages 89-99
Published: February 20, 1992
Released on J-STAGE: September 24, 2012
JOURNAL FREE ACCESSTwenty-one patients with active acromegaly and two patients with pituitary gigantism were treated with the long-acting somatostatin analogue octreotide (100-600μg/day, sc, two or three times daily or 300-1500μg daily by intermittent sc infusion) for 9-63 months. There was rapid clinical improvement. The fasting plasma GH levels were significantly suppressed (less than 50% of the values before treatment) in 17 patients and were normalized (less than 5ng/ml) in 6 patients (27.3%). Plasma IGF-I levels were lowered by 50% and were normalized in 7 out of 18 cases. The effect of octreotide on pituitary tumor size was evaluated in 13 patients. In 4 cases, the shrinkage of the pituitary tumor was detected by computed tomographic scans and/or magnetic resonance imaging studies. The drug was generally well tolerated. However, there were probably newly formed gallstones in two patients during the therapy. Our study suggests that octreotide is an effective and relatively safe new approach for treating active acromegaly and gigantism.View full abstractDownload PDF (1061K) -
Naoki ITOH, Yoshiaki KUMAMOTO, Hiroshi MARUTA, Taiji TSUKAMOTO, Hitosh ...1992 Volume 68 Issue 2 Pages 100-110
Published: February 20, 1992
Released on J-STAGE: September 24, 2012
JOURNAL FREE ACCESSA case of latent Addison's disease accompanied by hypogonadotropic hypogonadism and dwarfism is described.
A 20-year-old man was admitted to our department complaining of short stature and immature development of the external genitalia. Pigmentation was most evident on the fingers and face. Endocrinologically, serum ACTH level was very high, and serum cortisol level was in the lower limit of the normal range. Serum aldosterone and adrenal androgen levels were below their normal ranges. Based on these clinical and laboratory findings, the patient was diagnosed as having latent Addison's disease.
Serum LH did not respond to a bolus injection of LH-RH. However, after 3 days administration of LH-RH, the response of serum LH to a bolus injection of LH-RH was enhanced. Serum testosterone level was not increased after the administration of hCG. These findings suggested a hypothalamic cause for the hypogonadism. It was indicated that short stature was apparently caused by GH neurosecretory dysfunction, since nocturnal GH secretion was below that in normal males and the response of GH to the administration of arginine was normal.
In regard to the thyroid function, the peak of serum TSH after a bolus injection of TRH was delayed compared with normal subjects, and although serum T4 level was high, the basal metabolic rate was very low. This suggests that there is tissue resistance to the elevated thyroid hormone.View full abstractDownload PDF (840K) -
Mari HOSHIYAMA1992 Volume 68 Issue 2 Pages 111-118
Published: February 20, 1992
Released on J-STAGE: September 24, 2012
JOURNAL FREE ACCESSA 79-year old man with hypertension, hypokalemic metabolic alkallosis, hyporeninemia and hypoaldosteronemia was studied. Blood pressure fell and serum potassium returned to normal after sodium restriction and the administration of triamterene. Serum DHEA, DOC, corticosterone, 18-OH-corticosterone, 11-deoxy-cortisol, cortisol were within normal range. Adrenal CT scanning did not reveal an adrenal tumor. The excretions of urinary kallikrein and prostaglandin E2 were within the normal range. Although an atrophic juxtaglomerular apparatus and arteriosclerotic change were observed by renal biopsy, there was no evidence of hypokalemic nephropathy. From these results, it is suggested that this patient has a defect in handling sodium and potassium in the distal tubules. This is similar to that observed in Liddle's syndrome.View full abstractDownload PDF (1055K)
- |<
- <
- 1
- >
- >|